Rand. Clinical Trial of High Dose Immunoblative Thera

Petri, Michelle A.

Abstract

This is a phase II, open label study that compares the efficacy of intravenous monthly iv. cyclophosphamide (NIH protocol) to high dose intravenous cyclophosphamide (immunoablative protocol) in the treatment of moderate to severe SLE. Patients will be followed for 24 months after therapy.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• Type: Research and Development Contracts (N01)
• Project #: N01AR092243-000
• Application #: 6158400
• Project Start: 1999-09-30
• Project End: 2004-09-29
• Budget Start: 1999-09-30
• Budget End: 2000-09-29
• Fiscal Year: 1999

Institution

• Name: Johns Hopkins University
• Department: Internal Medicine/Medicine
• Type: Schools of Medicine
• DUNS #: 045911138
• City: Baltimore
• State: MD
• Country: United States
• Zip Code: 21218

Publications

Petri, Michelle; Brodsky, Robert A; Jones, Richard J et al. (2010) High-dose cyclophosphamide versus monthly intravenous cyclophosphamide for systemic lupus erythematosus: a prospective randomized trial. Arthritis Rheum 62:1487-93